Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.57 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.57 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.50 |
| ▸ | CSF1R | P07333 | 1/20 | 0.50 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.44 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.44 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29793572 | 1.00 | PDE4A (0.57) | PDE4APDE4BPDE4CPDE4DCYP1A2 | |
| SCHEMBL28863471 | 0.91 | PDE4A (0.75) | PDE4APDE4BPDE4CPDE4DCYP1A2 | |
| SCHEMBL29416410 | 0.83 | PDE4A (0.57) | PDE4APDE4BPDE4CPDE4DCYP1A2 | |
| SCHEMBL401110 | 0.83 | PDE4A (0.57) | PDE4APDE4BPDE4CPDE4DCYP1A2 | |
| Hydrochloric Acid SCHEMBL5739823 | 0.81 | PDE4A (0.55) | PDE4APDE4BPDE4CPDE4DCYP1A2 | |
| SCHEMBL17557663 | 0.80 | CNR1 (0.54) | — | |
| SCHEMBL3734931 | 0.79 | HTT (0.49) | CYP1A2CYP2D6EGFRALDH1A1LMNA | |
| SCHEMBL12844378 | 0.79 | CSF1R (0.51) | CYP1A2CYP2D6EGFRALDH1A1LMNA | |
| SCHEMBL182875 | 0.79 | LMNA (0.57) | PDE4APDE4BPDE4CPDE4DCYP1A2 | |
| SCHEMBL6590076 | 0.79 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4DEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250026752-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2025-01-23 | — | — | US | disclosed |
| US-20240382482-A1 | PLASMA KALLIKREIN INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2024-11-21 | — | — | US | disclosed |
| EP-4308228-A1 | PLASMA KALLIKREIN INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2024-01-24 | — | — | EP | disclosed |
| CN-117396474-A | Plasma kallikrein inhibitors | 武田药品工业株式会社 | 2024-01-12 | — | — | CN | disclosed |
| WO-2023192665-A2 | T-TYPE CALCIUM CHANNEL MODULATORS AND METHODS OF USE THEREOF | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023064588-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY (US) | 2023-04-20 | — | — | WO | disclosed |
| CN-112300141-B | Quinazoline-containing myricetin derivative, and preparation method and application thereof | 贵州大学 | 2023-04-18 | — | — | CN | disclosed |
| WO-2022197756-A1 | PLASMA KALLIKREIN INHIBITORS | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| CN-114773278-A | Quinazoline compound and application thereof in antivirus | 苏州大学 | 2022-07-22 | — | — | CN | disclosed |
| CN-113004210-A | Quinazoline-4-selenium salt compound, preparation method and biological activity | 鲁东大学 | 2021-06-22 | — | — | CN | disclosed |
| US-5576322-A | Anti-ischemic 2,4-diaminoquinazolines | EISAI CO., LTD. (JP) | 1996-11-19 | — | — | US | disclosed |
| WO-1996009294-A1 | SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE IN MEDICINE | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-03-28 | — | — | WO | disclosed |
| EP-0607439-A1 | NITROGENOUS HETEROCYCLIC COMPOUND | Eisai Co., Ltd. (JP) | 1994-07-27 | — | — | EP | disclosed |
| US-4808715-A | HYPERTENSIVE AGENTS | JOHN WYETH & BROTHER LIMITED (GB) | 1989-02-28 | — | — | US | disclosed |
| US-4734510-A | HYPOTENSIVE AGENTS | JOHN WYETH & BROTHER LIMITED (GB) | 1988-03-29 | — | — | US | disclosed |
| US-4640920-A | HYPOTENSIVE AGENTS | JOHN WYETH & BROTHER LIMITED (GB) | 1987-02-03 | — | — | US | disclosed |
| US-4464375-A | ANALGESIC, ANTIINFLAMMATORY | SANKYO CO., LTD. (JP) | 1984-08-07 | — | — | US | disclosed |
| US-4323680-A | 4-Aminoquinazoline compounds useful as agricultural fungicides | SANKYO COMPANY LIMITED (JP) | 1982-04-06 | — | — | US | disclosed |
| US-4322420-A | Method of using 4-anilinoquinazoline derivatives as analgesic and anti-inflammatory agents | SANKYO COMPANY LIMITED (JP) | 1982-03-30 | — | — | US | disclosed |
| US-4213987-A | 4-AMINOQUINAZOLINES | SANKYO COMPANY LIMITED (JP) | 1980-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026752-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM4, CHRM5, CHRM2 | PDE4A 106/4885PDE4B 134/4885PDE4C 111/4885 |
| US-20240382482-A1 | PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | PDE4A 1596/4885PDE4B 1643/4885PDE4C 1454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.